CH Biotech R&D Co., Ltd. (TPE:6534)
Taiwan
· Delayed Price · Currency is TWD 93.40
-2.50 (-2.61%)
Apr 29, 2026, 1:30 PM CST
CH Biotech R&D Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Net Income | 464 | 476.39 | 463.29 | 465.42 | 291.5 | Upgrade
|
| Depreciation & Amortization | 212.63 | 188.47 | 164.34 | 138.51 | 95.33 | Upgrade
|
| Other Amortization | 1.49 | 1.29 | 1.48 | 1.18 | 1.32 | Upgrade
|
| Loss (Gain) From Sale of Assets | 0.52 | -0.31 | -1.07 | -0.57 | -0.11 | Upgrade
|
| Loss (Gain) on Equity Investments | 3.1 | 0.26 | 0.05 | - | - | Upgrade
|
| Stock-Based Compensation | - | - | 1.24 | - | - | Upgrade
|
| Provision & Write-off of Bad Debts | 11.19 | - | - | - | - | Upgrade
|
| Other Operating Activities | 8.44 | -65.57 | 43.98 | 13.03 | 41.05 | Upgrade
|
| Change in Accounts Receivable | -94.37 | -56.76 | -72.77 | 127.84 | -124.69 | Upgrade
|
| Change in Inventory | -33.56 | -1.7 | 52.96 | -54.46 | -82.64 | Upgrade
|
| Change in Accounts Payable | 0.21 | -2.66 | -0.36 | -11.09 | 13.94 | Upgrade
|
| Change in Unearned Revenue | -0.16 | -0.14 | 0.17 | -0.05 | -0.15 | Upgrade
|
| Change in Other Net Operating Assets | 15.54 | -0.81 | 5.85 | 19.17 | 28.81 | Upgrade
|
| Operating Cash Flow | 589.02 | 538.44 | 659.15 | 698.97 | 264.36 | Upgrade
|
| Operating Cash Flow Growth | 9.39% | -18.31% | -5.70% | 164.40% | 13.50% | Upgrade
|
| Capital Expenditures | -123.34 | -588.42 | -113.68 | -113.89 | -71.92 | Upgrade
|
| Sale of Property, Plant & Equipment | 0.3 | 0.32 | 2.61 | 1.23 | 0.23 | Upgrade
|
| Cash Acquisitions | - | -3.55 | - | - | - | Upgrade
|
| Sale (Purchase) of Intangibles | -4.23 | -1.54 | -1.04 | -3.26 | - | Upgrade
|
| Investment in Securities | - | - | -29.4 | - | - | Upgrade
|
| Other Investing Activities | -13.56 | -1.58 | -1.38 | -1.31 | 26.95 | Upgrade
|
| Investing Cash Flow | -140.84 | -594.77 | -142.89 | -117.22 | -44.75 | Upgrade
|
| Short-Term Debt Issued | 915 | 665.21 | 480 | 450 | 381 | Upgrade
|
| Long-Term Debt Issued | - | 413.3 | 475.6 | 595.6 | - | Upgrade
|
| Total Debt Issued | 915 | 1,079 | 955.6 | 1,046 | 381 | Upgrade
|
| Short-Term Debt Repaid | -840 | -570.17 | -410 | -518 | -436 | Upgrade
|
| Long-Term Debt Repaid | -184.49 | -546.51 | -620.69 | -776.34 | -124.85 | Upgrade
|
| Total Debt Repaid | -1,024 | -1,117 | -1,031 | -1,294 | -560.85 | Upgrade
|
| Net Debt Issued (Repaid) | -109.49 | -38.18 | -75.09 | -248.74 | -179.85 | Upgrade
|
| Issuance of Common Stock | 0.3 | 0.1 | - | - | - | Upgrade
|
| Common Dividends Paid | -421.48 | -369.05 | -473.77 | -126.63 | -42.21 | Upgrade
|
| Other Financing Activities | -0.41 | 0.92 | 442.26 | - | - | Upgrade
|
| Financing Cash Flow | -531.08 | -406.21 | -106.6 | -375.37 | -222.06 | Upgrade
|
| Foreign Exchange Rate Adjustments | -1.84 | 1.46 | 0.25 | 2.64 | -0.55 | Upgrade
|
| Net Cash Flow | -84.73 | -461.08 | 409.91 | 209.01 | -3 | Upgrade
|
| Free Cash Flow | 465.68 | -49.98 | 545.47 | 585.08 | 192.43 | Upgrade
|
| Free Cash Flow Growth | - | - | -6.77% | 204.04% | 53.91% | Upgrade
|
| Free Cash Flow Margin | 25.60% | -3.06% | 36.01% | 40.80% | 18.89% | Upgrade
|
| Free Cash Flow Per Share | 4.51 | -0.48 | 5.57 | 5.93 | 1.96 | Upgrade
|
| Cash Interest Paid | 16.95 | 14.98 | 17.41 | 16.19 | 13.87 | Upgrade
|
| Cash Income Tax Paid | 98.64 | 179.74 | 76.18 | 90.18 | 27.21 | Upgrade
|
| Levered Free Cash Flow | 359.89 | -201.89 | 446.3 | 411.22 | 111.1 | Upgrade
|
| Unlevered Free Cash Flow | 370.49 | -192.52 | 456.8 | 421.73 | 119.78 | Upgrade
|
| Change in Working Capital | -112.35 | -62.07 | -14.14 | 81.4 | -164.74 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.